Comparison of Osteosarcoma Aggregated Tumour Models with Human Tissue by Multimodal Mass Spectrometry Imaging
Osteosarcoma (OS) is the most common primary bone malignancy and largely effects adolescents and young adults, with 60% of patients under the age of 25. There are multiple cell models of OS described in vitro that express the specific genetic alterations of the sarcoma. In the work reported here, mu...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-07-01
|
| Series: | Metabolites |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2218-1989/11/8/506 |
| _version_ | 1827684828593520640 |
|---|---|
| author | Lucy E. Flint Gregory Hamm Joseph D. Ready Stephanie Ling Catherine J. Duckett Neil A. Cross Laura M. Cole David P. Smith Richard J. A. Goodwin Malcolm R. Clench |
| author_facet | Lucy E. Flint Gregory Hamm Joseph D. Ready Stephanie Ling Catherine J. Duckett Neil A. Cross Laura M. Cole David P. Smith Richard J. A. Goodwin Malcolm R. Clench |
| author_sort | Lucy E. Flint |
| collection | DOAJ |
| description | Osteosarcoma (OS) is the most common primary bone malignancy and largely effects adolescents and young adults, with 60% of patients under the age of 25. There are multiple cell models of OS described in vitro that express the specific genetic alterations of the sarcoma. In the work reported here, multiple mass spectrometry imaging (MSI) modalities were employed to characterise two aggregated cellular models of OS models formed using the MG63 and SAOS-2 cell lines. Phenotyping of the metabolite activity within the two OS aggregoid models was achieved and a comparison of the metabolite data with OS human tissue samples revealed relevant fatty acid and phospholipid markers. Although, annotations of these species require MS/MS analysis for confident identification of the metabolites. From the putative assignments however, it was suggested that the MG63 aggregoids are an aggressive tumour model that exhibited metastatic-like potential. Alternatively, the SAOS-2 aggregoids are more mature osteoblast-like phenotype that expressed characteristics of cellular differentiation and bone development. It was determined the two OS aggregoid models shared similarities of metabolic behaviour with different regions of OS human tissues, specifically of the higher metastatic grade. |
| first_indexed | 2024-03-10T08:36:38Z |
| format | Article |
| id | doaj.art-f2726bcdd41a49d6a1aeac6eff90899a |
| institution | Directory Open Access Journal |
| issn | 2218-1989 |
| language | English |
| last_indexed | 2024-03-10T08:36:38Z |
| publishDate | 2021-07-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Metabolites |
| spelling | doaj.art-f2726bcdd41a49d6a1aeac6eff90899a2023-11-22T08:39:18ZengMDPI AGMetabolites2218-19892021-07-0111850610.3390/metabo11080506Comparison of Osteosarcoma Aggregated Tumour Models with Human Tissue by Multimodal Mass Spectrometry ImagingLucy E. Flint0Gregory Hamm1Joseph D. Ready2Stephanie Ling3Catherine J. Duckett4Neil A. Cross5Laura M. Cole6David P. Smith7Richard J. A. Goodwin8Malcolm R. Clench9Centre for Mass Spectrometry Imaging, Biomolecular Research Centre, Sheffield Hallam University, Sheffield S1 1WB, UKImaging and Data Analytics, Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge CB4 0WG, UKCentre for Mass Spectrometry Imaging, Biomolecular Research Centre, Sheffield Hallam University, Sheffield S1 1WB, UKImaging and Data Analytics, Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge CB4 0WG, UKCentre for Mass Spectrometry Imaging, Biomolecular Research Centre, Sheffield Hallam University, Sheffield S1 1WB, UKCentre for Mass Spectrometry Imaging, Biomolecular Research Centre, Sheffield Hallam University, Sheffield S1 1WB, UKCentre for Mass Spectrometry Imaging, Biomolecular Research Centre, Sheffield Hallam University, Sheffield S1 1WB, UKCentre for Mass Spectrometry Imaging, Biomolecular Research Centre, Sheffield Hallam University, Sheffield S1 1WB, UKImaging and Data Analytics, Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge CB4 0WG, UKCentre for Mass Spectrometry Imaging, Biomolecular Research Centre, Sheffield Hallam University, Sheffield S1 1WB, UKOsteosarcoma (OS) is the most common primary bone malignancy and largely effects adolescents and young adults, with 60% of patients under the age of 25. There are multiple cell models of OS described in vitro that express the specific genetic alterations of the sarcoma. In the work reported here, multiple mass spectrometry imaging (MSI) modalities were employed to characterise two aggregated cellular models of OS models formed using the MG63 and SAOS-2 cell lines. Phenotyping of the metabolite activity within the two OS aggregoid models was achieved and a comparison of the metabolite data with OS human tissue samples revealed relevant fatty acid and phospholipid markers. Although, annotations of these species require MS/MS analysis for confident identification of the metabolites. From the putative assignments however, it was suggested that the MG63 aggregoids are an aggressive tumour model that exhibited metastatic-like potential. Alternatively, the SAOS-2 aggregoids are more mature osteoblast-like phenotype that expressed characteristics of cellular differentiation and bone development. It was determined the two OS aggregoid models shared similarities of metabolic behaviour with different regions of OS human tissues, specifically of the higher metastatic grade.https://www.mdpi.com/2218-1989/11/8/506osteosarcomaDESImass spectrometry imagingLA-ICP-MSmetabolomicsimaging mass cytometry |
| spellingShingle | Lucy E. Flint Gregory Hamm Joseph D. Ready Stephanie Ling Catherine J. Duckett Neil A. Cross Laura M. Cole David P. Smith Richard J. A. Goodwin Malcolm R. Clench Comparison of Osteosarcoma Aggregated Tumour Models with Human Tissue by Multimodal Mass Spectrometry Imaging Metabolites osteosarcoma DESI mass spectrometry imaging LA-ICP-MS metabolomics imaging mass cytometry |
| title | Comparison of Osteosarcoma Aggregated Tumour Models with Human Tissue by Multimodal Mass Spectrometry Imaging |
| title_full | Comparison of Osteosarcoma Aggregated Tumour Models with Human Tissue by Multimodal Mass Spectrometry Imaging |
| title_fullStr | Comparison of Osteosarcoma Aggregated Tumour Models with Human Tissue by Multimodal Mass Spectrometry Imaging |
| title_full_unstemmed | Comparison of Osteosarcoma Aggregated Tumour Models with Human Tissue by Multimodal Mass Spectrometry Imaging |
| title_short | Comparison of Osteosarcoma Aggregated Tumour Models with Human Tissue by Multimodal Mass Spectrometry Imaging |
| title_sort | comparison of osteosarcoma aggregated tumour models with human tissue by multimodal mass spectrometry imaging |
| topic | osteosarcoma DESI mass spectrometry imaging LA-ICP-MS metabolomics imaging mass cytometry |
| url | https://www.mdpi.com/2218-1989/11/8/506 |
| work_keys_str_mv | AT lucyeflint comparisonofosteosarcomaaggregatedtumourmodelswithhumantissuebymultimodalmassspectrometryimaging AT gregoryhamm comparisonofosteosarcomaaggregatedtumourmodelswithhumantissuebymultimodalmassspectrometryimaging AT josephdready comparisonofosteosarcomaaggregatedtumourmodelswithhumantissuebymultimodalmassspectrometryimaging AT stephanieling comparisonofosteosarcomaaggregatedtumourmodelswithhumantissuebymultimodalmassspectrometryimaging AT catherinejduckett comparisonofosteosarcomaaggregatedtumourmodelswithhumantissuebymultimodalmassspectrometryimaging AT neilacross comparisonofosteosarcomaaggregatedtumourmodelswithhumantissuebymultimodalmassspectrometryimaging AT lauramcole comparisonofosteosarcomaaggregatedtumourmodelswithhumantissuebymultimodalmassspectrometryimaging AT davidpsmith comparisonofosteosarcomaaggregatedtumourmodelswithhumantissuebymultimodalmassspectrometryimaging AT richardjagoodwin comparisonofosteosarcomaaggregatedtumourmodelswithhumantissuebymultimodalmassspectrometryimaging AT malcolmrclench comparisonofosteosarcomaaggregatedtumourmodelswithhumantissuebymultimodalmassspectrometryimaging |